Zobrazeno 1 - 10
of 58
pro vyhledávání: '"R. A. Pinkerton"'
Autor:
R. Jason Pinkerton
Publikováno v:
IEEE Transactions on Professional Communication. 61:348-349
The author of this book builds a case for designers, marketers, and stakeholders in the global marketplace to incorporate multicultural and international considerations into all aspects of their products and services. The book demonstrates the long-t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e78c7f630daefad77e612653b9c5269
https://doi.org/10.1109/tpc.2018.2857239
https://doi.org/10.1109/tpc.2018.2857239
Autor:
Michael Ka Keu Wong, Martin Earle, R. A. Pinkerton, William Ferri, Khalid Matin, Robert Volkin, Ramesh K. Ramanathan, Samuel Wieand, Monica Troetschel, Samuel A. Jacobs, Thomas J. Richards, Terry Evans, David M. Friedland
Publikováno v:
American Journal of Clinical Oncology. 28:439-444
Objective: We tested the hypothesis that the combination of trimetrexate (TMTX) and capecitabine (CAP) would be active in patients with previously treated metastatic colorectal cancer (CRC). Because the optimum dose of this combination was unknown, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9ce4f25e160232051954f7557849fbe
https://doi.org/10.1097/01.coc.0000170797.36351.3a
https://doi.org/10.1097/01.coc.0000170797.36351.3a
Autor:
Marwan Fakih, Nathan Bahary, Amy Schmotzer, Ramesh K. Ramanathan, Theodore L. Crandall, Ronald G. Stoller, Stewart L. Lancaster, R. A. Pinkerton, Douglas M. Potter, Barry C. Lembersky, Benedito A. Carneiro, Smitha S. Krishnamurthi
Publikováno v:
Clinical colorectal cancer. 11(1)
Background Irinotecan and weekly cetuximab (I+C) is a standard second-line regimen for metastatic colorectal cancer (mCRC). This study investigated the safety and efficacy of every 2 weeks I+C in patients with mCRC. Patients and Methods Patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef2aa7d196b0763fa3125550eb9ce63e
https://pubmed.ncbi.nlm.nih.gov/21813336
https://pubmed.ncbi.nlm.nih.gov/21813336
Autor:
R E, PINKERTON
Publikováno v:
The Ohio State medical journal. 43(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c4d0617310c2a212abddf6f6a4c1827e
https://pubmed.ncbi.nlm.nih.gov/20241315
https://pubmed.ncbi.nlm.nih.gov/20241315
Publikováno v:
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 32(7)
To determine the agreement between two ophthalmologists in the evaluation of two important funduscopic features related to acute retinal artery occlusion: retinal cloudy swelling and visible retinal emboli.An interobserver variability study in which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::34d76ed73762c90d87f95668a2845adc
https://pubmed.ncbi.nlm.nih.gov/9435975
https://pubmed.ncbi.nlm.nih.gov/9435975
Publikováno v:
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 32(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::376680d285a62cbb115ccb13ed9cc023
https://pubmed.ncbi.nlm.nih.gov/9818126
https://pubmed.ncbi.nlm.nih.gov/9818126
Autor:
J. Franklin Viverette, Mohammad Abbas, Vida Almario Passero, John K. Waas, Ryan Kennedy, Markus Y. Mapara, Anastasios Raptis, Jennifer L. Osborn, Min Sun, Amy K. O’Sullivan, Terry Evans, Jing-Zhou Hou, Diane Gardner, G. David Roodman, Theodore L. Crandall, Suzanne Lentzsch, Daniel Petro, Robert L. Redner, Lijun Dai, Robert Volkin, Daniel P. Normolle, Carrie Andreas, L. Pietragallo, Ronald Fierro, Vincent Reyes, Yongli Shuai, Stanley M. Marks, R. A. Pinkerton
Publikováno v:
Blood. 118:4142-4142
Abstract 4142 Introduction: High dose chemotherapy combined with autologous stem cell transplantation (ASCT) as opposed to conventional chemotherapy improved progression free survival (PFS) and overall survival (OS) in multiple myeloma (MM) and is cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::496185b8585b70b9cd64faebbceb5754
https://doi.org/10.1182/blood.v118.21.4142.4142
https://doi.org/10.1182/blood.v118.21.4142.4142
Autor:
Ramesh K. Ramanathan, Rajesh Sehgal, D.M. Potter, R. A. Pinkerton, B.C. Lembersky, K. K. Rajasenan, Theodore L. Crandall, Edward P. Balaban, P. Kane
Publikováno v:
European Journal of Cancer Supplements. 7:339
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd4f4910393a877bfebdc1f8cfe379ee
https://doi.org/10.1016/s1359-6349(09)71153-x
https://doi.org/10.1016/s1359-6349(09)71153-x
Autor:
Smitha S. Krishnamurthi, R. A. Pinkerton, Marwan Fakih, S. Lancaster, B. A. Carneiro, Theodore L. Crandall, Douglas M. Potter, Barry C. Lembersky, Nathan Bahary, Ramesh K. Ramanathan
Publikováno v:
Journal of Clinical Oncology. 27:e15088-e15088
e15088 Background: I + C is a standard second line mCRC regimen. Our study investigated the efficacy and safety of a biweekly I + C combination in patients (pts) with mCRC. Methods: mCRC pts who failed 1st line fluoropyrimidine/oxaliplatin regimens a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d5db19cd38e1724a826c8e399cdfd3b
https://doi.org/10.1200/jco.2009.27.15_suppl.e15088
https://doi.org/10.1200/jco.2009.27.15_suppl.e15088
Autor:
Theodore L. Crandall, Ramesh K. Ramanathan, C. Kinney, R. A. Pinkerton, Douglas M. Potter, P. Kane, Edward P. Balaban, Rajesh Sehgal, K. K. Rajasenan, Barry C. Lembersky
Publikováno v:
Journal of Clinical Oncology. 26:4061-4061
4061 Background: CapOx and Bev is becoming a standard regimen for advanced CRC utilizing Cap on a d 1–14 schedule every 3 wks. However optimal doses and schedules of Cap with Ox and Bev needs continued evaluation. Intermittent wkly Cap (3,500 mg/m2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::880f35c5b93ef72aed9882cb82191cef
https://doi.org/10.1200/jco.2008.26.15_suppl.4061
https://doi.org/10.1200/jco.2008.26.15_suppl.4061